RESUMEN
Trastuzumab deruxtecan (T-DXd, DS-8201) is a targeted antibody-drug conjugate that specifically targets human epidermal growth factor receptor 2 (HER2). In 2019, it was approved by the US Food and Drug Administration for the treatment of HER2-positive breast cancer. However, ongoing research is exploring its potential efficacy in other solid tumors, such as non-small-cell lung cancer and colorectal cancer, as well as in tumors with low HER2 levels. It is important to examine the safety and effectiveness of trastuzumab deruxtecan in these various types of solid tumors, as some studies have raised concerns about potential serious adverse events associated with its use. In this meta-analysis, we conducted a comprehensive search of PubMed, EMBASE, Cochrane Library, and Web of Science to identify randomized controlled trials (RCTs) that evaluated the efficacy and safety of trastuzumab deruxtecan in solid tumors. We used RevMan 5.4 software to perform a meta-analysis, calculating odds ratios (OR), risk ratios (RR), and weighted mean differences (WMD) with 95% confidence intervals (CIs). After an exhaustive search, we identified three articles that met our inclusion criteria, which included a total of 1268 patients. The results of the meta-analysis showed that the treatment group had significantly higher overall survival (WMD=5.12, 95% CI (2.79, 7.44), P<0.0001), progression-free survival (WMD=3.45, 95% CI (0.8, 6.1), P=0.01), overall response rate (OR=6.49, 95% CI (4.90, 8.58), P<0.00001), and disease control rate (OR=4.68, 95% CI (2.78, 7.89), P<0.00001), TRAEs (RR=6.93, 95% CI (2.06, 23.25), P=0.002). However, there was no significant difference in TRAEs≥3 (RR=1.08, 95% CI (0.75, 1.56), P=0.68) between the trials. Based on the available evidence, trastuzumab deruxtecan appears to be an effective and safe treatment option for HER2-positive solid tumors. Although the number of studies included in this analysis is limited, ongoing trials are being conducted, further evaluating its potential in various solid tumors. The results of these trials will enhance our understanding of trastuzumab deruxtecan and potentially expand its applications, bringing hope to more patients with solid tumors.
RESUMEN
To quantitatively assess the health benefits brought by the implementation of the Action Plan of Air Pollution Prevention and Control, we firstly analyzed the spatial and temporal changes of PM2.5 population-weighted concentrations over China from 2013 to 2017. The BenMAP model was used to analyze the differences in premature death between the PM2.5 baseline scenario in 2013 and the control scenario in 2017 in 338 prefecture-level cities nationwide, so as to quantitatively analyze the number of premature deaths in 31 provinces. The results show that compared with other provinces, the largest reduction in premature deaths due to the significant decrease of PM2.5 concentration occurred in the Beijing-Tianjin-Hebei region and its surrounding regions, and the environmental health benefits from air quality have been greatly improved. The results show that from 2013 to 2017 the population weighted PM2.5 concentration was decreasing year by year due to the significant decrease in PM2.5 concentration; Beijing, Tianjin, Hebei, and the surrounding areas witnessed the largest reduction in premature deaths. In 2017, the number of avoided premature deaths in 280 prefecture-level cities nationwide increased, but declined in 58 cities. Taking the target value of the first phase of the WHO transition period (an annual average PM2.5 concentration of 35 µg·m-3) as the control scenario, it is estimated that the number of premature deaths in 2013 was approximately 101293, and in 2017 was approximately 41080. The implementation of the Action Plan helped to avoid approximately 60213 premature deaths. According to the method of 'willingness to pay', the monetary benefits are estimated to be approximately 54.97 billion yuan.
